The strongest association was seen with monoclonal antibody CGRP inhibitors, a category that includes drugs including erenumab and galcanezumab. The reduced risk was particularly noticeable in older adults, women, and people with chronic migraine, suggesting that these new migraine treatments may have additional benefits beyond headache prevention.
